tbuckley/cabot-search huggingface dataset:
Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples
Authors: Timothy A. Bates, Hans C. Leier, Zoe L. Lyski, James R. Goodman, Marcel E. Curlin, William B. Messer, Fikadu G. Tafesse
Journal: JAMA (2021)

Vaccination with 2 doses of the BNT162b2 vaccine (Pfizer-BioNTech) reportedly provides 95% protection from COVID-19. 1 However, patient age is known to contribute to the risk of
Nidogen-2 Maintains the Contractile Phenotype of Vascular Smooth Muscle Cells and Prevents Neointima Formation via Bridging Jagged1-Notch3 Signaling
Authors: Chenfeng Mao, Zihan Ma, Yiting Jia, Weihao Li, Nan Xie, Guizhen Zhao, Baihui Ma, Fang Yu, Jinpeng Sun, Yuan Zhou, Qinghua Cui, Yi Fu, Wei Kong
Journal: Circulation (2021)

Background: How the extracellular matrix (ECM) microenvironment modulates the contractile phenotype of vascular smooth muscle cells (VSMCs) and confers vascular homeostasis remains elusive. Methods: To explore the key ECM proteins in the maintenance of the contractile phenotype of VSMCs, we applied protein-protein interaction network analysis to explore novel ECM proteins associated with the VSMC phenotype. By combining in vitro and in vivo genetic mice vascular injury models, we identified nidogen-2, a basement membrane glycoprotein, as a key ECM protein for maintenance of vascular smooth muscle cell identity. Results: We collected a VSMC phenotype–related gene dataset by using Gene Ontology annotation combined with a literature search. A computational analysis of protein-protein interactions between ECM protein genes and the genes from the VSMC phenotype–related gene dataset revealed the candidate gene nidogen-2, a basement membrane glycoprotein involved in regulation of the VSMC phenotype. Indeed, nidogen-2–deficient VSMCs exhibited loss of contractile phenotype in vitro, and compared with wild-type mice, nidogen-2 –/ – mice showed aggravated post–wire injury neointima formation of carotid arteries. Further bioinformatics analysis, coimmunoprecipitation assays, and luciferase assays revealed that nidogen-2 specifically interacted with Jagged1, a conventional Notch ligand. Nidogen-2 maintained the VSMC contractile phenotype via Jagged1-Notch3 signaling but not Notch1 or Notch2 signaling. Nidogen-2 enhanced Jagged1 and Notch3 interaction and subsequent Notch3 activation. Reciprocally, Jagged1 and Notch3 interaction, signaling activation, and Jagged1-triggered VSMC differentiation were significantly repressed in nidogen-2–deficient VSMCs. In accordance, the suppressive effect of Jagged1 overexpression on neointima formation was attenuated in nidogen-2 –/– mice compared with wild-type mice. Conclusions: Nidogen-2 maintains the contractile phenotype of VSMCs through Jagged1-Notch3 signaling in vitro and in vivo. Nidogen-2 is required for Jagged1-Notch3 signaling.
Correction: Lumen-apposing stents versus plastic stents in the management of pancreatic pseudocysts: a large, comparative, international, multicenter study
Authors: Juliana Yang, Yen-I Chen, Shai Friedland, Ian Holmes, Christopher Paiji, Ryan Law, Amy Hosmer, Tyler Stevens, Franco Matheus, Rishi Pawa, Nihar Mathur, Divyesh Sejpal, Sumant Inamdar, Tyler M. Berzin, Christopher J. DiMaio, Sanchit Gupta, Patrick S. Yachimski, Andrea Anderloni, Alessandro Repici, Theodore James, Laith H. Jamil, Mel Ona, Simon K. Lo, Srinivas Gaddam, Markus Dollhopf, Nuha Alammar, Eugenie Shieh, Majidah Bukhari, Vivek Kumbhari, Vikesh Singh, Olaya Brewer, Omid Sanaei, Lea Fayad, Saowanee Ngamruengphong, Eun Ji Shin, Todd H. Baron, Mouen A. Khashab
Journal: Endoscopy (2019)

Correction to: Lumen-apposing stents versus plastic stents in the management of pancreatic pseudocysts: a large, comparative, international, multicenter studyEndoscopy eFirstDOI: 10.1055/a-0759-1353
Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness
Authors: Jennifer M Yeh, Kathryn P Lowry, Clyde B Schechter, Lisa R Diller, Grace O’Brien, Oguzhan Alagoz, Gregory T Armstrong, John M Hampton, Melissa M Hudson, Wendy Leisenring, Qi Liu, Jeanne S Mandelblatt, Diana L Miglioretti, Chaya S Moskowitz, Paul C Nathan, Joseph P Neglia, Kevin C Oeffinger, Amy Trentham-Dietz, Natasha K Stout
Journal: JNCI Journal of the National Cancer Institute (2021)

Abstract Background Early initiation of breast cancer screening is recommended for high-risk women, including survivors of childhood cancer treated with chest radiation. Recent studies suggest that female survivors of childhood leukemia or sarcoma treated without chest radiation are also at elevated early onset breast cancer risk. However, the potential clinical benefits and cost-effectiveness of early breast cancer screening among these women are uncertain. Methods Using data from the Childhood Cancer Survivor Study, we adapted 2 Cancer Intervention and Surveillance Modeling Network simulation models to reflect the elevated risks of breast cancer and competing mortality among leukemia and sarcoma survivors. Costs and utility weights were based on published studies and databases. Outcomes included breast cancer deaths averted, false-positive screening results, benign biopsies, and incremental cost-effectiveness ratios. Results In the absence of screening, the lifetime risk of dying from breast cancer among survivors was 6.8% to 7.0% across models. Early initiation of annual mammography with breast magnetic resonance imaging screening between ages 25 and 40 years would avert 52.6% to 64.3% of breast cancer deaths. When costs and quality-of-life impacts were considered, screening starting at age 40 years was the only strategy with an incremental cost-effectiveness ratio below the $100 000 per quality-adjusted life-year (QALY) gained cost-effectiveness threshold ($27 680 to $44 380 per QALY gained across models). Conclusions Among survivors of childhood leukemia or sarcoma, early initiation of breast cancer screening at age 40 years may reduce breast cancer deaths by half and is cost-effective. These findings could help inform screening guidelines for survivors treated without chest radiation.
Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study
Authors: Maria Carmona-Iragui, Daniel Alcolea, Isabel Barroeta, Laura Videla, Laia Muñoz, Kathyrn L Van Pelt, Frederick A Schmitt, Donita D Lightner, Lisa M Koehl, Gregory Jicha, Silvia Sacco, Clotilde Mircher, Sarah E Pape, Rosalyn Hithersay, Isabel C H Clare, Anthony J Holland, Georg Nübling, Johannes Levin, Shahid H Zaman, Andre Strydom, Anne-Sophie Rebillat, Elizabeth Head, Rafael Blesa, Alberto Lleó, Juan Fortea
Journal: The Lancet Neurology (2021)
Vitamin D supplementation, lung function and asthma control in children with asthma and low vitamin D levels
Authors: Yueh-Ying Han, Erick Forno, Leonard B. Bacharier, Wanda Phipatanakul, Theresa W. Guilbert, Michael D. Cabana, Kristie Ross, Joshua Blatter, Franziska J. Rosser, Sandy Durrani, James Luther, Stephen R. Wisniewski, Juan C. Celedón
Journal: European Respiratory Journal (2021)

<b>Vitamin D supplementation, compared with placebo, had no significant effect on percent predicted lung function measures (FEV1, FVC or FEV1/FVC), asthma control, or asthma-related quality of life in children with asthma and low vitamin D levels</b>https://bit.ly/3ibbT4u
P-19 A multicentred phase II clinical trial on yttrium 90-resin microspheres followed by gemcitabine-cisplatin for treatment of locally advanced intra-hepatic cholangiocarcinoma
Authors: S. Chan, C. Chotipanich, S. Choo, S. Kwang, A. Worakitsitisatorn, D. Tai, W. Yong, R. Sundar, L. Li, S. Yu, P. Sungkasubun
Journal: Annals of Oncology (2021)
In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection
Authors: Francisco Javier Candel, Anne Santerre Henriksen, Christopher Longshaw, Yoshinori Yamano, Antonio Oliver
Journal: Clinical Microbiology and Infection (2021)

We assessed the activity of the novel siderophore cephalosporin, cefiderocol and selected other antibacterial agents against Gram-negative bacterial isolates in Europe.Isolates were obtained between 2013 and 2018 from European countries participating in the SIDERO-WT and SIDERO-Proteeae multinational surveillance studies. Isolates were categorised by infection site, focusing on bloodstream infections, hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP), complicated intra-abdominal infections and complicated urinary tract infections. Cefiderocol activity was compared with ceftazidime-avibactam, ceftolozane-tazobactam, colistin and meropenem using standard susceptibility testing methods. European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used to interpret susceptibility data.Isolates (n = 20 911) were collected from 145 sites in 24 countries in Europe, the highest proportion (34%) being from patients with HABP/VABP. Enterobacterales (66.6% of isolates) were more frequent than glucose non-fermenting species (33.4%) overall, with some differences between infection sites. Across all infection sites, the MIC50/MIC90 for cefiderocol was ≤0.5/≤2 mg/L for Enterobacter spp., ≤0.25/<2 mg/L for Klebsiella spp., 0.12/2 mg/L for Acinetobacter spp., ≤0.25/1 mg/L for Pseudomonas aeruginosa and ≤0.12/≤0.5 mg/L for Stenotrophomonas maltophilia. Across all infection sites, cefiderocol MICs were ≤2 mg/L for ≥96% of Enterobacter spp., ≥95% of Klebsiella spp., ≥90% of Acinetobacter spp. and ≥99% of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolates. Cefiderocol maintained high activity in carbapenem-resistant isolates, and the difference in activity between carbapenem-resistant (percentage susceptibility at EUCAST breakpoint: E. coli 77.8%, Klebsiella spp. 69.2%, Pseudomonas aeruginosa 97.5%, Acinetobacter spp. 90.7%, Stenotrophomonas maltophilia 99.6%) and carbapenem-susceptible (percentage susceptibility at EUCAST breakpoint: E. coli 99.4%, Klebsiella spp. 98.0%, Pseudomonas aeruginosa 99.7%, Acinetobacter spp. 94.9%) isolates was lower for cefiderocol than other agents.Cefiderocol had excellent activity against all Gram-negative species, independent of key infection site and carbapenem MIC. Cefiderocol is a useful addition to the therapeutic options available for these difficult-to-treat infections.
Leaving general practice: all GPs are on a continuum from staying to leaving
Authors: Richard Pratt
Journal: BMJ (2021)

Salisbury makes many strong points1 that resonate deeply with me and no doubt many others currently in general practice.

There is a metaphor implicitly interwoven into the description of the decision to stay or leave general practice—that of weighing scales, where reasons to stay are balanced against reasons to leave.

Given the escalating stress of work in general practice, much …
Comments on Computed Tomography for Evaluating Appendicitis—Reply
Authors: Kyung Hee Lee, Seungjae Lee, Ji Hoon Park
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
A Real-World Ethical Analysis of Contingency Measures Enacted for Crisis Standards of Care during the COVID-19 Pandemic
Authors: Joyeeta G. Dastidar
Journal: The American Journal of Bioethics (2021)

Click to increase image sizeClick to decrease image sizeThis article refers to:Between Usual and Crisis Phases of a Public Health Emergency: The Mediating Role of Contingency MeasuresThis article is referred to by:Ethics Frameworks and Beyond—Advancing Our Understanding of the Contingency Phase to Improve Health Care Quality During Public Health Emergencies
Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma
Authors: Eun Joo Kang, Myung-Ju Ahn, Chan-Young Ock, Keun-Wook Lee, Jung Hye Kwon, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Byung-Ho Nam, Sung-Bae Kim, Bhumsuk Keam
Journal: Clinical Cancer Research (2021)

The role of chemotherapy in adenoid cystic carcinoma (ACC) is controversial because ACC is usually stable without chemotherapy and the lack of randomized trials. Here, we conducted the first randomized trial to evaluate the efficacy of axitinib as compared with observation in ACC.In this multicenter, prospective phase II trial, we enrolled patients with recurrent or metastatic ACC whose cancer had progressed within the past 9 months. Patients were randomly assigned to either axitinib (5 mg twice daily) or observation at a 1:1 ratio. Crossover from observation to axitinib was permitted after progression. The primary endpoint was a 6-month progression-free survival (PFS) rate. The secondary endpoints included objective response rate (ORR), overall survival (OS), PFS, duration of response, and adverse events.Sixty patients were allocated to the axitinib or observation group, with response evaluation conducted in 54 patients. With a median follow-up of 25.4 months, the 6-month PFS rate was 73.0% with axitinib and 23.0% with observation. Median PFS was longer in the axitinib arm (10.8 months vs. 2.8 months, P < 0.001). The ORR of axitinib was 0.0%, but the disease control rate was 100.0% with axitinib and 51.9% with observation. Median OS was not reached with axitinib, but was 27.2 months with observation (P = 0.226). The most frequently reported adverse events for axitinib were oral mucositis and fatigue.In this first randomized trial in patients with ACC, axitinib significantly increased the 6-month PFS rate as compared with observation. (ClinicalTrials.gov number, NCT02859012).
Intestinal hypoxia-inducible factor 2α regulates lactate levels to shape the gut microbiome and alter thermogenesis
Authors: Qing Wu, Xianyi Liang, Kai Wang, Jun Lin, Xuemei Wang, Pengcheng Wang, Yangming Zhang, Qixing Nie, Huiying Liu, Zhipeng Zhang, Junhui Liu, Yanli Pang, Changtao Jiang
Journal: Cell Metabolism (2021)
Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
Authors: Imke Redeker, Katinka Albrecht, Joern Kekow, Gerd Rüdiger Burmester, Juergen Braun, Martin Schäfer, Angela Zink, Anja Strangfeld
Journal: Annals of the Rheumatic Diseases (2021)

To compare event and incidence rates of herpes zoster (HZ), also known as shingles, in patients with rheumatoid arthritis under treatment with conventional synthetic (cs), targeted synthetic (ts) or biologic (b) disease-modifying antirheumatic drugs (DMARDs).Patients were prospectively enrolled from 2007 until October 2020. Reported HZ events were assigned to ongoing treatments or those terminated within 1 month prior to the HZ event. Exposure-adjusted event rates (EAERs) of HZ were calculated per 1000 patient years (py) and adjusted HRs with 95% CIs computed. Inverse probability weights (IPW) were used to adjust for confounding by indication.Data of 13 991 patients (62 958 py) were analysed, with 559 HZ events reported in 533 patients. The EAER of HZ was highest for tsDMARDs (21.5, 95% CI 16.4 to 27.9), followed by B cell targeted therapy (10.3, 95% CI 8.0 to 13.0), monoclonal antitumour necrosis factor (anti-TNF) antibodies (9.3, 95% CI 7.7 to 11.2), interleukin 6 inhibitors (8.8, 95% CI 6.9 to 11.0), soluble TNF receptor fusion protein (8.6, 95% CI 6.8 to 10.8), T cell costimulation modulator (8.4, 95% CI 5.9 to 11.8) and csDMARDs (7.1, 95% CI 6.0 to 8.3). Adjusted for age, sex and glucocorticoids and weighted with IPW, tsDMARDs (HR 3.66, 95% CI 2.38 to 5.63), monoclonal anti-TNF antibodies (HR 1.63, 95% CI 1.17 to 2.28) and B cell targeted therapy (HR 1.57, 95% CI 1.03 to 2.40) showed a significantly higher risk compared with csDMARDs.Our results provide evidence for a 3.6-fold increased risk of HZ associated with tsDMARDs and an increased risk of HZ under bDMARDs compared with csDMARDs.
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women
Authors: Nicholas J. Boddicker, Chunling Hu, Jeffrey N. Weitzel, Peter Kraft, Katherine L. Nathanson, David E. Goldgar, Jie Na, Hongyan Huang, Rohan D. Gnanaolivu, Nicole Larson, Amal Yussuf, Song Yao, Celine M. Vachon, Amy Trentham-Dietz, Lauren Teras, Jack A. Taylor, Christopher E. Scott, Dale P. Sandler, Tina Pesaran, Alpa V. Patel, Julie R. Palmer, Irene M. Ong, Janet E. Olson, Katie O'Brien, Susan Neuhausen, Elena Martinez, Huiyan Ma, Sara Lindstrom, Loic Le Marchand, Charles Kooperberg, Rachid Karam, David J. Hunter, James M. Hodge, Christopher Haiman, Mia M. Gaudet, Chi Gao, Holly LaDuca, James V. Lacey, Jill S. Dolinsky, Elizabeth Chao, Brian D. Carter, Elizabeth S. Burnside, Kimberly A. Bertrand, Leslie Bernstein, Paul W. Auer, Christine Ambrosone, Siddhartha Yadav, Steven N. Hart, Eric C. Polley, Susan M. Domchek, Fergus J. Couch
Journal: Journal of Clinical Oncology (2021)

PURPOSE The prevalence of germline pathogenic variants (PVs) in established breast cancer predisposition genes in women in the general population over age 65 years is not well-defined. However, testing guidelines suggest that women diagnosed with breast cancer over age 65 years might have &lt; 2.5% likelihood of a PV in a high-penetrance gene. This study aimed to establish the frequency of PVs and remaining risks of breast cancer for each gene in women over age 65 years. METHODS A total of 26,707 women over age 65 years from population-based studies (51.5% with breast cancer and 48.5% unaffected) were tested for PVs in germline predisposition gene. Frequencies of PVs and associations between PVs in each gene and breast cancer were assessed, and remaining lifetime breast cancer risks were estimated for non-Hispanic White women with PVs. RESULTS The frequency of PVs in predisposition genes was 3.18% for women with breast cancer and 1.48% for unaffected women over age 65 years. PVs in BRCA1, BRCA2, and PALB2 were found in 3.42% of women diagnosed with estrogen receptor (ER)–negative, 1.0% with ER-positive, and 3.01% with triple-negative breast cancer. Frequencies of PVs were lower among women with no first-degree relatives with breast cancer. PVs in CHEK2, PALB2, BRCA2, and BRCA1 were associated with increased risks (odds ratio = 2.9-4.0) of breast cancer. Remaining lifetime risks of breast cancer were ≥ 15% for those with PVs in BRCA1, BRCA2, and PALB2. CONCLUSION This study suggests that all women diagnosed with triple-negative breast cancer or ER-negative breast cancer should receive genetic testing and that women over age 65 years with BRCA1 and BRCA2 PVs and perhaps with PALB2 and CHEK2 PVs should be considered for magnetic resonance imaging screening.
ABCG2 but Not ABCB1 RNA Levels at Diagnosis and during Treatment Correlates with Response to Imatinib and 2G-Tkis Front-Line Therapy in Chronic Phase CML Patients
Authors: Mario Tiribelli, Sara Di Giusto, Eleonora Toffoletti, Davide Griguolo, Domenico Penna, Giorgia Maccari, Marta Medeot, Renato Fanin, Daniela Damiani
Journal: Blood (2017)
Absolute Percent Deviation of IGHV Mutation As a Continuum Is Prognostically Relevant in Patients with CLL
Authors: Preetesh Jain, Jan A. Burger, Graciela Nogueras González, Rashmi Kanagal-Shamanna, Uri Rozovski, Constantine S. Tam, William G Wierda, Philip A Thompson, Nawid Sarwari, Rajyalakshmi Luthra, Andrew Quesada, Nitin Jain, Alessandra Ferrajoli, Hagop M. Kantarjian, Jorge E. Cortes, Susan M. O'Brien, Michael J. Keating, Zeev Estrov
Journal: Blood (2017)
High In-Hospital Mortality Rate in Patients with COVID-19 Receiving Extracorporeal Membrane Oxygenation in Germany: A Critical Analysis
Authors: Christian Karagiannidis, Stephan Strassmann, Michaela Merten, Thomas Bein, Wolfram Windisch, Patrick Meybohm, Steffen Weber-Carstens
Journal: American Journal of Respiratory and Critical Care Medicine (2021)
A Microfluidic Model Artery for Studying the Mechanobiology of Endothelial Cells
Authors: Hyeonji Yu, Dongwon Kang, Minji Whang, Taeyoung Kim, Jungwook Kim
Journal: Advanced Healthcare Materials (2021)

Abstract Recent vascular mechanobiology studies find that endothelial cells (ECs) convert multiple mechanical forces into functional responses in a nonadditive way, suggesting that signaling pathways such as those regulating cytoskeleton may be shared among the processes of converting individual forces. However, previous in vitro EC‐culture platforms are inherent with extraneous mechanical components, which may saturate or insufficiently activate the shared signaling pathways and accordingly, may misguide EC mechanobiological responses being investigated. Here, a more physiologically relevant model artery is reported that accurately reproduces most of the mechanical forces found in vivo, which can be individually varied in any combination to pathological levels to achieve diseased states. Arterial geometries of normal and diseased states are also realized. By mimicking mechanical microenvironments of early‐stage atherosclerosis, it is demonstrated that the elevated levels of the different types of stress experienced by ECs strongly correlate with the disruption of barrier integrity, suggesting that boundaries of an initial lesion could be sites for efficient disease progression.
Kupffer cell restoration after partial hepatectomy is mainly driven by local cell proliferation in IL-6-dependent autocrine and paracrine manners
Authors: Yeni Ait Ahmed, Yaojie Fu, Robim M. Rodrigues, Yong He, Yukun Guan, Adrien Guillot, Ruixue Ren, Dechun Feng, Juan Hidalgo, Cynthia Ju, Fouad Lafdil, Bin Gao
Journal: Cellular and Molecular Immunology (2021)
Long covid: reshaping conversations about medically unexplained symptoms
Authors: Sean L Davidson, David B Menkes
Journal: BMJ (2021)

Newman’s article, a linked patient commentary, and the tranche of rapid responses show how “long covid” has reignited debate about the causes and management of chronic fatigue syndrome.1 Rather than moving beyond the controversy, most of the ensuing arguments have fallen back into familiar grooves deepened by confirmation bias and dualistic thinking.123 On a more positive note, the intense media attention on and public interest in long covid present a golden opportunity to reshape and extend discussions about …